Comparative efficacy and safety of anti-infective drugs for patients with mild to severe COVID-19: A systematic review and network meta-analysis of randomized controlled trials
Ethiop. Med. j
; 61(2): 171-188, 2023. tables, figures
Article
in English
| AIM (Africa)
| ID: biblio-1426999
Responsible library:
CG1.1
ABSTRACT
Different anti-infecthe drugs have been proposedfor the treatment ofpatients with COVID-19. We carried out a network meta-analysis to assess their relath'e efficacy and safety. Methods:
We searched relevant databases for all randomized controlled trials that reported the efficacy and or safety ofany anti-infective drugs published up to April 30, 2022 for different outcomes. We did both painvise and network meta-analysis with 95% confidence intervals using afixed-effect model. We assessed studies for quality of evidence using an extension of the standard Grading ofRecommendations, Assessment, Development and Evaluation approach considering PConclusion:
This Network Meta-analysis suggests that Baricitinib plus Remdesivir is more effective than the other anti-infective drugs in treating patients with COVID-19 in terms of clinical recovery at 14 days, mortality and adverse events outcomes.
Fulltext
- https://indexmedicus.afro.who.int/iah/fulltext/Comparative efficacy and safety of anti infective drugs for patients with mild to severe COVID 19 A systematic review and network meta analysis of randomized controlled trials.pdf
- https://emjema.org/index.php/EMJ/article/view/2211/897
- https://fi-admin.bvsalud.org/document/view/cm8uy
Full text:
Available
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
/
SDG3 - Target 3.3 End transmission of communicable diseases
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Goal 9: Noncommunicable diseases and mental health
/
Goal 5: Medicines, vaccines and health technologies
/
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
COVID-19
/
Pneumonia
/
Other Respiratory Diseases
Database:
AIM (Africa)
Main subject:
Randomized Controlled Trial
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Controlled clinical trial
/
Systematic review
Limits:
Humans
Language:
English
Journal:
Ethiop. Med. j
Year:
2023
Document type:
Article
Institution/Affiliation country:
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University/ET
/
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences,/ET
/
Department of Statistics, Addis Ababa University, Addis Ababa/ET
/
ICenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa/ET
/
School of Psychology, Addis Ababa University, Addis Ababa/ET